This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeuroMetrix Officers Interviewed On Plans For Diabetes Market

Stock quotes in this article: NURO

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that in separate interviews Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., and Thomas T. Higgins, Chief Financial Officer, discussed milestones, product plans, and finances for 2012. The interview of Dr. Gozani is on GLX TV, a financial news network, at: http://www.youtube.com/watch?v=NvRKA5SLYuo&feature=youtu.be

Dr. Gozani noted that the company has recorded orders for over 350 NC-stat ® DPNCheck™ devices, the company’s point-of-care test for the detection of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects over 50% of people with diabetes and can lead to foot ulcers and amputation. He reiterated the company’s goal which is to achieve the placement of 1,000 NC-stat DPNCheck devices by the end of 2012. Among the company’s early customers is Wal-Mart Canada Corp. The NC-stat DPNCheck diagnostic test is performed with single-patient use biosensors. It is a “razor-razor blade” business model.

Dr. Gozani reviewed development progress for SENSUS™, the company’s second diabetes product which will extend the product line beyond diagnostics to therapeutics. SENSUS is intended to be used in the symptomatic relief and management of chronic intractable pain, such as painful diabetic neuropathy, a disabling complication of DPN. A premarket notification, or 510(k), was recently filed with the Food and Drug Administration (FDA). Subject to regulatory clearance, the company hopes to launch SENSUS by the end of 2012.

In an interview with CEOCFO http://ceocfointerviews.com/interviews/NURO-NeuroMetrix12.htm, Mr. Higgins reviewed 2012 milestones and also discussed those sectors of the overall diabetic peripheral neuropathy market which are most attractive to the company. Dr. Gozani and Mr. Higgins both pointed to near-term opportunities in retail medicine and managed care.

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit http://www.neurometrix.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs